Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Century Therapeutics (IPSC) EBITDA (2022 - 2025)

Historic EBITDA for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to -$34.4 million.

  • Century Therapeutics' EBITDA fell 1419.81% to -$34.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$27.2 million, marking a year-over-year increase of 7874.5%. This contributed to the annual value of -$126.4 million for FY2024, which is 578.14% up from last year.
  • Century Therapeutics' EBITDA amounted to -$34.4 million in Q3 2025, which was down 1419.81% from -$32.8 million recorded in Q2 2025.
  • In the past 5 years, Century Therapeutics' EBITDA ranged from a high of $76.5 million in Q1 2025 and a low of -$39.5 million during Q1 2022
  • Over the past 4 years, Century Therapeutics' median EBITDA value was -$31.8 million (recorded in 2022), while the average stood at -$25.6 million.
  • In the last 5 years, Century Therapeutics' EBITDA plummeted by 2437.46% in 2023 and then soared by 36940.62% in 2025.
  • Century Therapeutics' EBITDA (Quarter) stood at -$30.5 million in 2022, then decreased by 24.37% to -$38.0 million in 2023, then increased by 3.89% to -$36.5 million in 2024, then increased by 5.66% to -$34.4 million in 2025.
  • Its EBITDA stands at -$34.4 million for Q3 2025, versus -$32.8 million for Q2 2025 and $76.5 million for Q1 2025.